Clinical trials: Disorders, Blood Coagulation
Atrial Fibrillation
Low-dose NOAC Versus GDMT After LAAO
The increased risk of Atrial fibrillation (AF) regarding thromboembolic stroke is predominantly due to the formation and embolization of clots from within the left atrial appendage (LAA).
- Trial name
- RECORD-III (NCT05960721)
- Testing
- Rivaroxaban 15mg, Aspirin 100mg, Clopidogrel 75mg
- Where
- China
- Volunteers
- 4,220 people
- Sponsor
- Xijing Hospital
Hemophilia A
Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused…
- Trial name
- IMMUNHEMAC (NCT04805021)
- Testing
- no intervention
- Where
- 2 sites in France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Thrombotic Thrombocytopenic Purpura
Observational Study of the Use of octaplasLG®.
This observational study enrolls patients who have received at least one infusion of octaplasLG®. OctaplasLG® will be administered standard of care and observation occurs during the treatment and 24 hours after the end of…
- Trial name
- NCT03369314
- Testing
- octaplasLG®
- Where
- 14 sites in France
- Volunteers
- 263 people
- Sponsor
- Octapharma
Hemophilia A
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
The purpose of this study is to determine the effect of 3 doses of ADVATE rAHF-PFM on initial recovery (% increase [IU/dL] per IU/kg infused) and major single-infusion pharmacokinetic parameters.
- Trial name
- NCT00289536
- Testing
- Antihemophilic factor, recombinant, manufactured protein-free
- Where
- 8 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baxalta now part of Shire
Von Willebrand Disease, Type 2B
Impact of Von Willebrand Factor-platelet Aggregates in Patients With Type 2B Disease
The working hypothesis is that patients with Von Willebrand Disease-type 2B may have neurological symptoms due to the chronic formation of platelets/Von Willebrand Factor aggregates.
- Trial name
- Von2B (NCT05015244)
- Testing
- 3T (Tesla) Magnetic Resonance Imaging (MRI)
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Caen
Blood Biomarkers, Vasodilation
The Role of Eicosanoids in the Cardiovascular Actions of Inhaled Nanoparticles
Nanoparticles (NPs) are minute pieces of material to which we are exposed every day in the air we breathe. Some are naturally occurring and have no impact on health, whereas others are produced from urban air pollution and can…
- Conditions
- Blood Biomarkers, Vasodilation, Blood Clotting, Lung Function
- Trial name
- ECOARM (NCT03659864)
- Testing
- diesel exhaust particulate, carbon nanoparticles, small graphene oxide
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
This trial is studying the side effects and how well giving cyclophosphamide and busulfan followed by donor stem cell transplant works in treating patients with myelofibrosis, acute myeloid leukemia, or myelodysplastic syndrome.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT00445744
- Testing
- cyclophosphamide, busulfan, tacrolimus
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Disease, Hemophilia A
BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
The purpose of the study is to evaluate the effect of prophylactic treatment on the number of joint bleeds and quality of life in severe hemophilia A subjects compared to on-demand treatment in a one-group two-treatment schedule…
- Trial name
- NCT00586521
- Testing
- Kogenate (BAY14-2222)
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Bayer
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Gastro Esophageal Reflux
Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)
This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e.
- Trial name
- AREA21 (NCT05570448)
- Testing
- ARAT
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Midwest Veterans' Biomedical Research Foundation
Coronavirus Disease 2019
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections.
- Trial name
- NCT04401436
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic Thrombocytopenic Purpura
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study.
- Trial name
- PETIT2 (NCT01520909)
- Testing
- Eltrombopag
- Where
- 51 sites in United States, Argentina and 11 more
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Venous Stasis, Deep Venous Thrombosis
Effects of External Leg Compression Devices on Healing and Blood Clotting
This study aims to compare two different external calf compression devices applied in healthy individuals. These devices are commonly used in medical care in order to prevent the formation of blood clots, for example during…
- Conditions
- Venous Stasis, Deep Venous Thrombosis, Healing Wound
- Trial name
- NCT03050671
- Testing
- Intermittent Pneumatic Compression, Rapid, Intermittent Pneumatic Compression, Slow
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Uterine Cervical Dysplasia
Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial
In a randomized clinical trial of 120 women undergoing large loop excision of the transformation zone (LLETZ)-conization for cervical dysplasia, two coagulation modes, spray versus forced coagulation, will be compared.
- Trial name
- CONE-1 (NCT02330471)
- Testing
- Spray, Forced
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- Ruhr University of Bochum
Cardiac Surgical Procedures, Cardiopulmonary Bypass
Sequestration of Platelets Prior to Bypass Reduces Bleeding After Cardiac Surgery
Excessive bleeding is common after cardiac surgery. This may result in patients receiving a blood transfusion or suffering the life-threatening complication of cardiac tamponade.
- Conditions
- Cardiac Surgical Procedures, Cardiopulmonary Bypass, Blood Platelet Disorders, Blood Coagulation Disorders
- Trial name
- NCT00359398
- Testing
- Platelet rich plasma sequestration
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Wiskott-Aldrich Syndrome
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding.
- Trial name
- NCT02064933
- Where
- 43 sites in United States, Canada
- Volunteers
- 305 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
OM336 in Autoimmune Cytopenias
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
- Conditions
- AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
- Trial name
- NCT07083960
- Testing
- OM336
- Where
- 7 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Lakefront Biotherapeutics West LLC
COVID, Sars-CoV2
Preventing COVID-19 Complications With Low- and High-dose Anticoagulation
The ongoing COVID-19 pandemic affects millions of humans worldwide and has led to thousands of acute medical hospitalizations. There is evidence that hospitalized cases often suffer from an important infection-related…
- Trial name
- COVID-HEP (NCT04345848)
- Testing
- Enoxaparin
- Where
- 4 sites in Switzerland
- Volunteers
- 160 people
- Sponsor
- University Hospital, Geneva
Hemophilia
Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy
Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy).
- Trial name
- NCT05039008
- Testing
- Blood flow restriction
- Where
- Spain
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Investigación en Hemofilia y Fisioterapia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.